Parkinson’s UK to inject £1m into drug development
The charity is partnering with NRG Therapeutics Ltd to discover and develop a potential drug that could safeguard dopamine cells.
Read More
Tag: dopamine
Addex joins UK drug and brain research initiative
Swiss group Addex Therapeutics has joined a UK-based initiative established to study the role of the D1 receptor, the main dopamine receptor, in human brain function.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
